Effectiveness and safety of inhaled granulocyte-macrophage colony-stimulating factor therapy in idiopathic pulmonary alveolar proteinosis
OBJECTIVE: To investigate the effectiveness and safety of inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy in idiopathic pulmonary alveolar proteinosis (PAP).
METHODS: Ten PAP patients were enrolled, who were hospitalized in the Affiliated Drum Tower Hospital of Nanjing University Medical School from January 2012 to January 2014.All the patients were treated with inhaled GM-CSF therapy, high-dose therapy for 12 weeks, GM-CSF 150 µg twice a day on days 1-7, none for days 8-14, 6 cycles, low-dose therapy for 12 weeks, GM-CSF 150 µg inhaled once a day on days 1-7, none for days 8-14, 6 cycles, and followed-up for one year. Physiologic, serologic and radiologic features of the patients were analyzed.
RESULTS: After inhaled therapy, clinical symptoms, oxygenation indexes, pulmonary function of nine patients were improved, and high resolution CT (HRCT) showed ground-glass lesions reduced. After inhaled therapy for 6 months, the average level of arterial oxygen partial pressure (PaO₂) was significantly higher than that before therapy ((75.5 ± 7.0) vs (63.6 ± 8.9) mmHg (1 mmHg=0.133 kPa)), while alveolar-arterial oxygen pressure difference (P(A-a)O₂) was lower than before ((25.1 ± 7.1) vs (41.2 ± 13.5) mmHg) (both P<0.01). Similarly, vital capacity (VC)% predicted, forced vital capacity (FVC)% predicted and carbon monoxide diffusing capacity (DLCO)% predicted all improved after therapy ((77.3 ± 16.6)% vs (63.3 ± 16.6)%), (79.5 ± 17.6)% vs (64.9 ± 17.1)%), (69.4 ± 23.0)% vs (50.0 ± 19.9)%) (all P<0.01). The score of HRCT reduced after therapy for six months (P<0.05). While the levels of serum lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), CYFRA211 were unchanged. No serious adverse events occurred during observation.
CONCLUSION: Inhaled GM-CSF therapy is safe and effective.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Zhonghua yi xue za zhi - 95(2015), 34 vom: 08. Sept., Seite 2766-70 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Ding, Jingjing [VerfasserIn] |
|---|
| Themen: |
83869-56-1 |
|---|
| Anmerkungen: |
Date Completed 30.03.2016 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM255970684 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM255970684 | ||
| 003 | DE-627 | ||
| 005 | 20231224175626.0 | ||
| 007 | tu | ||
| 008 | 231224s2015 xx ||||| 00| ||chi c | ||
| 028 | 5 | 2 | |a pubmed24n0853.xml |
| 035 | |a (DE-627)NLM255970684 | ||
| 035 | |a (NLM)26711974 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Ding, Jingjing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and safety of inhaled granulocyte-macrophage colony-stimulating factor therapy in idiopathic pulmonary alveolar proteinosis |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.2016 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To investigate the effectiveness and safety of inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy in idiopathic pulmonary alveolar proteinosis (PAP) | ||
| 520 | |a METHODS: Ten PAP patients were enrolled, who were hospitalized in the Affiliated Drum Tower Hospital of Nanjing University Medical School from January 2012 to January 2014.All the patients were treated with inhaled GM-CSF therapy, high-dose therapy for 12 weeks, GM-CSF 150 µg twice a day on days 1-7, none for days 8-14, 6 cycles, low-dose therapy for 12 weeks, GM-CSF 150 µg inhaled once a day on days 1-7, none for days 8-14, 6 cycles, and followed-up for one year. Physiologic, serologic and radiologic features of the patients were analyzed | ||
| 520 | |a RESULTS: After inhaled therapy, clinical symptoms, oxygenation indexes, pulmonary function of nine patients were improved, and high resolution CT (HRCT) showed ground-glass lesions reduced. After inhaled therapy for 6 months, the average level of arterial oxygen partial pressure (PaO₂) was significantly higher than that before therapy ((75.5 ± 7.0) vs (63.6 ± 8.9) mmHg (1 mmHg=0.133 kPa)), while alveolar-arterial oxygen pressure difference (P(A-a)O₂) was lower than before ((25.1 ± 7.1) vs (41.2 ± 13.5) mmHg) (both P<0.01). Similarly, vital capacity (VC)% predicted, forced vital capacity (FVC)% predicted and carbon monoxide diffusing capacity (DLCO)% predicted all improved after therapy ((77.3 ± 16.6)% vs (63.3 ± 16.6)%), (79.5 ± 17.6)% vs (64.9 ± 17.1)%), (69.4 ± 23.0)% vs (50.0 ± 19.9)%) (all P<0.01). The score of HRCT reduced after therapy for six months (P<0.05). While the levels of serum lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), CYFRA211 were unchanged. No serious adverse events occurred during observation | ||
| 520 | |a CONCLUSION: Inhaled GM-CSF therapy is safe and effective | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Carcinoembryonic Antigen |2 NLM | |
| 650 | 7 | |a Granulocyte-Macrophage Colony-Stimulating Factor |2 NLM | |
| 650 | 7 | |a 83869-56-1 |2 NLM | |
| 700 | 1 | |a Xiao, Yonglong |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Jinghong |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Liyun |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Yuying |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lulu |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Hanyi |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Hourong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua yi xue za zhi |d 1994 |g 95(2015), 34 vom: 08. Sept., Seite 2766-70 |w (DE-627)NLM000566861 |x 0376-2491 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2015 |g number:34 |g day:08 |g month:09 |g pages:2766-70 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2015 |e 34 |b 08 |c 09 |h 2766-70 | ||